Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actavis And Valeant Now Squaring Off For IBS Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Viberzi and Xifaxan share an indication and an approval date, but not much else.


Related Content

Valeant Backs Strategy With Solid Deal Record
Keeping Track: New Drugs For IBS, LAM; New NDAs for HCV and Hyperkalemia
Capital Allocation In The Age Of Shareholder Activism
FDA Quietly Consults Patients To Understand Vimizim's Six-Minute Walk Significance
Patient-Focused Drug Development At 10: Where Does It Go From Here?
Lotronex REMS’ Verification Process Should Be Electronic, FDA Panel Says
Data On Length Of Symptom Relief Could Improve Xifaxan Trial, Panel Members Suggest
IBS-D Lead May Go To Tioga With Salix Required To Run Another Trial


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts